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We looked for cross-reactive antibodies in 122 persons 
with paired serum samples collected during the 2009 
pandemic of inﬂ   uenza virus A(H1N1)pdm09. Eight (12%) 
of 67 persons with A(H1N1)pdm09 infection conﬁ  rmed 
by reverse transcription PCR and/or serology also 
seroconverted to the seasonal A/Brisbane/59/2007 (H1N1) 
virus, compared with 1 (2%) of 55 A(H1N1)pdm09-negative 
persons (p<0.05).
T
he role of seasonal 2008–09 trivalent inactivated 
inﬂ   uenza vaccines in protecting against inﬂ  uenza 
A(H1N1)pdm09 virus remains controversial (1). Recent 
reports indicated that prior infections with seasonal 
inﬂ   uenza A viruses protected against A(H1N1)pdm09 
virus infection, suggesting the presence of cross-reactive 
antibodies (2). Several studies have proposed that humoral 
immunity and conserved B- and T-cell epitopes contribute 
to heterosubtypic protection (3,4). Our objective was to 
determine whether A(H1N1)pdm09 infection induced 
cross-reactive antibodies against seasonal inﬂ  uenza  A 
(H1N1) and A (H3N2) viruses.
The Study
This investigation was part of a trial evaluating 
A(H1N1)pdm09 transmission among household contacts, 
conducted during the ﬁ   rst wave of the 2009 pandemic 
(May–July 2009) in Quebec City, Quebec, Canada (5). 
Clinical data and samples were serially obtained from 
index case-patients and their contacts in 42 households. 
Nasopharyngeal secretions were collected from all 
participants during the ﬁ  rst visit and tested by 2 different 
assays: a conventional reverse transcription PCR (RT-
PCR) targeting the hemagglutinin gene of A(H1N1)pdm09 
virus (6) and a universal RT-PCR targeting the matrix gene 
of all inﬂ  uenza A viruses (7). Blood was collected from 
persons >7 years of age at their initial visit (acute-phase 
sample) and 3–4 weeks later (convalescent-phase sample). 
Serum was tested by microneutralization assay according 
to World Health Organization standard protocols with 
minor modiﬁ  cations (8).
This serologic study comprised 122 persons from 
the 42 households. Twenty-four persons were RT-PCR–
conﬁ   rmed index case-patients (median age 15 years, 
range 7–56 years), and 98 were household contacts 
(median age 30.5 years, range 7–61 years), of whom 34 
also were positive for A(H1N1)pdm09 virus by RT-
PCR. For 67 patients (median age 20 years, range 7–61 
years), A(H1N1)pdm09 was conﬁ  rmed by RT-PCR and/
or microneutralization assay: 10 (15%) by RT-PCR 
alone, 9 (13%) by microneutralization assay alone, and 
48 (72%) by RT-PCR and microneutralization assay. 
Of the 67 A(H1N1)pdm09-infected persons, 8 (12%) 
seroconverted to A/Brisbane/59/2007 (A[H1N1] vaccine 
strain for 2008–09) (online Appendix Table, wwwnc.
cdc.gov/EID/article/18/7/11-1680-TA1.htm). Seven A/
Brisbane/59/2007 seroconverters were RT-PCR positive 
and A(H1N1)pdm09 seroconverters, and 1 was RT-PCR 
positive and a A(H1N1)pdm09 nonseroconverter. In 
comparison, 1 (2%) of the 55 A(H1N1)pdm09-negative 
patients seroconverted to A/Brisbane/59/2007 (Fisher 
exact test, p<0.05). Seasonal inﬂ  uenza viruses were not 
circulating in the province of Quebec at the time of this 
study. Only 1 of 9 A/Brisbane/59/2007 seroconverters 
had previously received the inactivated 2008–09 seasonal 
inﬂ  uenza vaccines. No participants were vaccinated against 
A(H1N1)pdm09 virus, and none received antiviral therapy 
or prophylaxis.
We then assessed whether this cross-reactivity 
was limited to the A/Brisbane/59/2007 strain, the most 
recent seasonal A (H1N1) virus to have circulated before 
A(H1N1)pdm09 virus, or whether it was broader. To 
this end, we tested all paired serum samples against an 
older seasonal A (H1N1) inﬂ   uenza virus, i.e., A/New 
Caledonia/20/1999 (H1N1 vaccine strain used during the 
2000–01 through 2006–07 seasons), and a past A(H3N2) 
virus, i.e., A/Panama/7/2004 (H3N2 vaccine component 
used during the 2000–01 through 2003–04 seasons). 
Seven (10%) A(H1N1)pdm09 virus–positive persons also 
seroconverted to A/New Caledonia/20/1999(H1N1), all of 
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whom were RT-PCR-positive and A(H1N1)pdm09 virus 
seroconverters, whereas none of the A(H1N1)pdm09 
virus–negative persons seroconverted to this older strain 
(p<0.05). On the other hand, seroconversion rates for A/
Panama/7/2004(H3N2) did not differ signiﬁ  cantly between 
A(H1N1)pdm09 virus-positive (9%) and -negative (5%) 
patients. In addition, we identiﬁ  ed 4 (6%) persons with 
laboratory-conﬁ   rmed A(H1N1)pdm09 virus infections 
who seroconverted to both seasonal (H1N1) viruses and 
2 (3%) who seroconverted to A/Brisbane/59/2007(H1N1) 
and A/Panama/2007/99(H3N2) (Table). Participant 44C, 
a household contact of a conﬁ  rmed case-patient with a 
negative RT-PCR for A(H1N1)pdm09 and low antibody 
titers in the convalescent-phase serum, showed cross-
neutralizing antibodies meeting 4-fold seroconversion 
criteria for A/Brisbane/59/2007(H1N1) and A/Panama/7/
2004(H3N2).
Conclusions
During this study, the only inﬂ  uenza virus detected in 
the province of Quebec was A(H1N1)pdm09 virus. Yet, 
8 (12%) of 67 A(H1N1)pdm09 virus–infected persons 
in our study had a concomitant signiﬁ   cant increase in 
microneutralization antibody titers against the most recent 
A/Brisbane/59/2007(H1N1) strain, of whom 5 persons had 
4–8-fold, 2 had 16-fold, and 1 had 32-fold rises. In addition, 
4 of these 8 persons also seroconverted to an older A/New 
Caledonia/20/1999(H1N1) virus, of whom 3 persons had 
4-fold and 1 had 16-fold rises between acute-phase and 
convalescent-phase serum. The cross-reactivity observed 
in the study population does not seem to be completely 
subtype speciﬁ   c because some persons also showed 
rising titers against an old inﬂ  uenza A (H3N2) strain (A/
Panama/2007/99), although in this case, seroconversion 
rates did not differ signiﬁ  cantly between A(H1N1)pdm09 
virus–positive and –negative persons.
A recent study in Hong Kong of 28 paired serum 
samples showed that infection with the pandemic virus could 
broaden cross-reactive immunity to other recent subtype H1 
swine viruses. In contrast to our study, perhaps because of 
the small number of participants or older age of A(H1N1)
pdm09 virus–positive case-patients (30.5 vs. 20 years), no 
cross-reactive response was shown against the more recent 
seasonal inﬂ  uenza virus A/HK/400599/2008(H1N1) (9).
We could not determine the extent to which past 
seasonal inﬂ  uenza vaccinations and/or natural infections 
contributed to the generation of cross-neutralizing 
antibodies to A(H1N1)pdm09 and the seasonal inﬂ  uenza 
strains. Our next step will be to investigate potential cross-
neutralizing determinants between these seasonal and 
pandemic viruses. Neutralizing antibodies that bind to 
the stalk region of HA2 have been shown to confer broad 
cross-neutralizing activity against several subtypes of 
viruses across clades and to provide protection in animal 
models (10,11). Six of the 8 persons who seroconverted 
to A/Brisbane/59/2007(H1N1) by microneutralization 
assay did not meet the 4-fold criteria by hemagglutinin 
inhibition assay (data not shown), suggesting that the 
cross-reactivity might result from conserved epitopes in the 
stalk region of HA2 or in other proteins. Greenbaum et al. 
recently showed that, overall, 49% of the epitopes reported 
in recently circulating seasonal A (H1N1) strains were 
conserved in the A(H1N1)pdm09 virus (12). Speciﬁ  cally, 
31%, 41%, and 69% of the B-cell, CD4+ and CD8+ T-cell 
epitopes, respectively, were conserved. Natural infection 
with A(H1N1)pdm09 virus also could have elicited cross-
reactive responses against internal components of older 
viral strains (13). We ﬁ  nd intriguing the elaboration of 
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Table. Clinical features and microneutralization antibody titers against influenza A(H1N1)pdm09 and seasonal influenza A viruses of 






Titers, acute phase/convalescent phase (-fold increase) 







(H3N2)  ARI ILI 
39A/7  +  +  +    <10/160 (16)  <10/320 (32)  <10/160 (16)  320/160 (0) 
39C/11  +  +  +    <10/40 (4)  10/160 (16)  <10/40 (4)  2,560/2,560 (0) 
49A/28  +  +  +    <10/160 (16)  40/160 (4)  <10/20 (2)  320/320 (0) 
49B/23  +  +  +    <10/640 (64)  <10/160 (16)  40/160 (4)  40/40 (0) 
55F/7  +  +  +    <10/40 (4)  10/40 (4)  20/80 (4)  10/10 (0) 
16C/7  +  +  +    <10/80 (8)  160/320 (2)  40/160 (4)  80/80 (0) 
56A/12  +  +  +    <10/40 (4)  80/320 (4)  40/80 (2)  2,560/2,560 (0) 
65B/40  +  +  +    <10/320 (32)  <10/20 (2)  10/40 (4)  320/320 (0) 
03E/17  +  +  +    <10/80 (8)  40/80 (2)  160/160 (0)  640/5,120 (8) 
10B/14  +  +  +    <10/80 (8)  20/20 (0)  80/320 (4)  640/640 (0) 
11C/61†  +  +  +    <10/1,280 (128)  40/160 (4)  160/160 (0)  320/1,280 (4) 
44B/9  +  +  +    <10/<80 (8)  1,280/640 (0)  1,280/1,280 (0)  160/640 (4) 
44C/44  –  +  –    <10/20 (2)  10/80 (8)  80/80 (0)  160/640 (4) 
58A/13  +  +  +    <10/80 (8)  <10/20 (2)  10/20 (2)  1,280/5,120 (4) 
58B/43  +  +  –    <10/160 (16)  <10/10 (0)  <10/<10 (0)  20/160 (8) 
*RT-PCR, reverse transcription PCR; ARI, acute respiratory illness (i.e., presence of t2 of the following signs/symptoms: fever [t37.8°C] or feverishness, 
cough, sore throat, or rhinorrhea); ILI, influenza-like illness (i.e., fever and cough and/or sore throat); +, positive; –, negative. 
†Received seasonal vaccine in 2008–09. cross-reactive neutralizing antibodies to more recently 
circulating inﬂ  uenza A (H1N1) strains as a result of novel 
A(H1N1)pdm09 virus infection, whereas the reverse has 
not generally been evident in serosurveys for cross-reactive 
A(H1N1)pdm09 antibody, except in elderly persons who 
had substantial cross-reactive antibodies to A(H1N1)
pdm09 virus (14,15). Unfortunately, because of the small 
sample size of our study and lack of serum from children <7 
years of age, we could not assess whether cross-reactivity 
was an age-dependent phenomenon. However, all but 3 of 
the cross-reactive seroconverters (13/16 [81%]) were 7–30 
years of age. To explore preferential responses to the original 
infecting virus (original antigenic sin), we assessed cross-
reactivity for the older A/New Caledonia/99(H1N1) virus 
that was potentially the priming antigen for some of our 
younger participants or was closely related to the priming 
antigen in older participants. However, seroconversion 
rates for A/New Caledonia (10%) were comparable to 
those of the more recent A/Brisbane/59/2007(H1N1) strain 
(12%), and thus we could not distinguish original antigenic 
sin on that basis. These antigens may have been too closely 
related antigenically to demonstrate that in this young 
cohort.
Our work supports the notion that natural A(H1N1)
pdm09 virus infection induces broad heterosubtypic (H1 
and even H3) responses. It also highlights the need for 
further investigation of the mechanisms behind cross-
protection because they could be keys to creating improved 
inﬂ  uenza vaccines with broader protection.
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